Quality of life CFQ‐R scores (treatment burden domain and respiratory domain) · adults and children with cystic fibrosis
1 finding from 1 review
Serum deposition Cmax · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
FEV1 % predicted · adults and children with cystic fibrosis
1 finding from 1 review
Time to next exacerbation · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant satisfaction or preference · adults and children with cystic fibrosis
Summary of findings ‐ nebulisers for delivering dornase alfa:… may leads to lower participant satisfaction or preference: compared with VMT (low certainty).
1 finding from 1 review
Treatment time (minutes) · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serum deposition Cmax · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next exacerbation · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant satisfaction or preference · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · adults and children with cystic fibrosis
1 finding from 1 review
no estimate extracted
25 participants
Low
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
Morning showed no clear difference in FEV1 (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).
1 finding from 1 review
no estimate extracted
25 participants
Low
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis
Morning showed no clear difference in FVC (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).
1 finding from 1 review
no estimate extracted
25 participants
Low
Measures of QoL and symptom scores · adults and children with cystic fibrosis
1 finding from 1 review
no estimate extracted
25 participants
Low
FEF25-75 · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF
1 finding from 1 review
Lung function: FEV1 mL (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FEV1 mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review